ReviewScience translational medicine2019
"Inactive" ingredients in oral medications.
Review in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Accelerated discovery of thermostable mRNA-lipid nanoparticle vaccines using data-efficient AI.Nature biotechnology · 2026Article
- The exposome and inflammatory bowel disease: a framework for primary and primordial prevention.Nature reviews. Gastroenterology & hepatology · 2026Review
- Article
- Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of Levocarnitine.Pharmaceutical medicine · 2026Review
- Unveiling the bioactive landscape of drug inactive ingredients (DIGs) using deep transfer learning.Acta pharmaceutica Sinica. B · 2026Article
- Using sentiment analysis to quantify the relative desirability and acceptability of drug-product attributes.JAMIA open · 2026Article
- Article
- Unlocking the Potential Use of Berry Anthocyanins as Pharmaceutical Excipients and Nanocarriers: Evidence from the Last Decades.International journal of molecular sciences · 2026Review
- Clinical and radiological outcomes of directed treatment transitions from GilenyaMultiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Designing lipid nanoparticles using a transformer-based neural network.Nature nanotechnology · 2025Article
- Presence of gluten and soy derived excipients in medicinal products and their implications on allergen safety and labeling.Scientific reports · 2025Article
- Challenges for switching central nervous system and psychiatric medication products: A review of the literature.Journal of psychopharmacology (Oxford, England) · 2025Review
- A call to action for adverse drug event (ADE) detection and prevention.Frontiers in digital health · 2025Review
- Anaphylaxis to cow's milk protein in a probiotic not detected by the electronic medical record.JPGN reports · 2024Article
- Inconsistent excipient listings in DailyMed: implications for drug safety.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Silica-based microencapsulation used in topical dermatologic applications.Archives of dermatological research · 2023Review
- Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies.Pharmaceutics · 2023Review
- Can Pharmaceutical Excipients Threaten the Aquatic Environment? A Risk Assessment Based on the MicrotoxMolecules (Basel, Switzerland) · 2023Article
- Feasibility of a drug allergy registry-based excipient allergy database and call for universal mandatory drug ingredient disclosure: the case of PEG.Frontiers in allergy · 2023Article
- Proton Pump Inhibitors in Allergy: Benefits and Risks.The journal of allergy and clinical immunology. In practice · 2022Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
Oral forms of medications contain "inactive" ingredients to enhance their physical properties. Using data analytics, we characterized the abundance and complexity of inactive ingredients in approved medications. A majority of medications contain ingredients that could cause adverse reactions, underscoring the need to maximize the tolerability and safety of medications and their inactive ingredients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.